Validating the portal population of the United Kingdom Multiple Sclerosis Register (2018)

Type of publication:
Journal article

Middleton R.M.; Rodgers W.J.; Akbari A.; Tuite-Dalton K.; Lockhart-Jones H.; Griffiths D.; Noble D.G.; Jones K.H.; Ford D.V.; Chataway J.; Schmierer K.; Rog D.; Galea I.; Al-Din A.; Craner M.; Evangelou N.; Harman P.; Harrower T.; Hobart J.; Husseyin H.; Kasti M.; Kipps C.; McDonnell G.; *Owen C.; Pearson O.; Rashid W.; Wilson H.

Multiple Sclerosis and Related Disorders; Aug 2018; vol. 24 ; p. 3-10

The UK Multiple Sclerosis Register (UKMSR) is a large cohort study designed to capture ‘real world’ information about living with multiple sclerosis (MS) in the UK from diverse sources. The primary source of data is directly from people with Multiple Sclerosis (pwMS) captured by longitudinal questionnaires via an internet portal. This population’s diagnosis of MS is self-reported and therefore unverified. The second data source is clinical data which is captured from MS Specialist Treatment centres across the UK. This includes a clinically confirmed diagnosis of MS (by Macdonald criteria) for consented patients. A proportion of the internet population have also been consented at their hospital making comparisons possible. This dataset is called the ‘linked dataset’. The purpose of this paper is to examine the characteristics of the three datasets: the selfreported portal data, clinical data and linked data, in order to assess the validity of the self-reported portal data. The internet (n = 11,021) and clinical (n = 3,003) populations were studied for key shared characteristics. We found them to be closely matched for mean age at diagnosis (clinical = 37.39, portal = 39.28) and gender ratio (female %, portal = 73.1, clinical = 75.2). The Two Sample Kolmogorov-Smirnov test was for the continuous variables to examine is they were drawn from the same distribution. The null hypothesis was rejected only for age at diagnosis (D = 0.078, p < 0.01). The populations therefore, were drawn from different distributions, as there are more patients with relapsing disease in the clinical cohort. In all other analyses performed, the populations were shown to be drawn from the same distribution. Our analysis has shown that the UKMSR portal population is highly analogous to the entirely clinical (validated) population. This supports the validity of the self-reported diagnosis and therefore that the portal population can be utilised as a viable and valid cohort of people with Multiple Sclerosis for study.